ReviewNature aging2021
Toward the recognition and management of sarcopenia in routine clinical care.
Review in Nature aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Fructooligosaccharides and ellagic acid synergistically enhance muscular endurance via targeting gut microbial urolithin A biosynthesis.Journal of advanced research · 2026Article
- Strengthening muscle for healthy ageing: innovative treatments for sarcopenia.Nature reviews. Drug discovery · 2026Review
- Sarcopenia and paraspinal muscle degeneration in adults with spinal deformity surgery: a systematic review and proposal of the Global Alignment and Proportion modification framework.Asian spine journal · 2026Article
- Longitudinal study on the relationship between extracellular water distribution changes and muscle mass in severe sarcopenia patients using multi-frequency bioelectrical impedance analysis combined with phase angle measurements.European geriatric medicine · 2026Article
- Longitudinal bidirectional associations among sarcopenia risk, social isolation, and frailty in Chinese older adults using an item response theory-derived frailty index.Frontiers in public health · 2026Observational
- Development and external validation of a composite biomarker-based machine learning model for sarcopenia risk stratification in patients with cardiovascular disease.Frontiers in cardiovascular medicine · 2026Article
- Early physiological phenotypes and survival outcomes in advanced non-small cell lung cancer: a longitudinal study of dynamic muscle loss and functional decline.Frontiers in oncology · 2026Article
- Metabolite biomarkers present in urine predict alterations in skeletal muscle associated with sarcopenia.Frontiers in aging · 2026Article
- Edentulism as an independent risk factor for sarcopenia: evidence from cross-sectional and longitudinal analyses based on the CHARLS cohort.BMC oral health · 2025Article
- Overcoming Implementation Barriers in Frailty Management in Cardiology: From Consensus to Bedside.JACC. Asia · 2025Article
- Therapeutic silicate biomaterials for sarcopenia treatment by inhibiting inflammation and enhancing muscle regeneration through regulation of Sarcolipin/SIRT signaling pathway.Bioactive materials · 2025Article
- Improved Strength Prediction Combining MRI Biomarkers of Muscle Quantity and Quality.NMR in biomedicine · 2025Article
- Sarcopenia - the need for an Asian perspective.Aging clinical and experimental research · 2025Review
- Predictive efficacy of waist-related indices for sarcopenic obesity incidence in Chinese older adults: a nationwide cohort study.BMC geriatrics · 2025Article
- Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment.Nutrients · 2025Review
- Association between indoor ventilation frequency and low muscle mass among older adults in China: a national cross-sectional research.Scientific reports · 2025Article
- Prediction of sarcopenia at different time intervals: an interpretable machine learning analysis of modifiable factors.BMC geriatrics · 2025Article
- Multi-organ frailty is enhanced by periodontitis-induced inflammaging.Inflammation and regeneration · 2025Article
- The relationship between intrinsic capacity and sarcopenia in middle-aged and older Chinese populations: the mediating influence of a novel nutritional index.Frontiers in public health · 2025Article
- High-Intensity Interval Training Mitigates Sarcopenia and Suppresses the Myoblast Senescence Regulator EEF1E1.Journal of cachexia, sarcopenia and muscle · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia, the age-associated decline in skeletal muscle mass and function, is a major cause of functional decline and mortality in older adults. Despite its importance, sarcopenia often remains unrecognized and inadequately managed in routine clinical care. A major hinderance to its clinical integration is the variation in diagnostic tools for sarcopenia. Diagnostic tools include those of the European Working Group on Sarcopenia in Older People (versions 1 and 2), those of the Asian Working Group for Sarcopenia (versions 1 and 2), and that of the Sarcopenia Definition and Outcomes Consortium. The management decision process of sarcopenia warrants an evaluation of risk factors such as a sedentary lifestyle, inadequate exercise, poor nutritional intake, smoking, depression and living circumstances. Herein, we provide an evidence-based update of the prevention and management of sarcopenia and propose practical information to facilitate the disease's adoption into routine care.
Indexed as
Identifiers
37118343What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.